Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04091945 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS
A Phase 2 study of Acute Ischemic Stroke, sponsored by Lumosa Therapeutics Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 10
- Study locations
NCT04091945 is a Phase 2 study of Acute Ischemic Stroke that has completed, run by Lumosa Therapeutics Co.. The registered enrollment target is 24 participants, below the 351-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (93% lower). The trial reports 10 study locations across 5 states.
The verdict
NCT04091945, a Phase 2 study of Acute Ischemic Stroke, has completed, sponsored by Lumosa Therapeutics Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a multicenter, double-blind, single-dose, randomized, and placebo-controlled prospective Phase IIa clinical study, designed to evaluate LT3001 drug product versus placebo/control in subjects with AIS.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LT3001 Drug Product
Study Locations (10)
Other
- Kaohsiung Medical University Chung-Ho Memorial Hospital - Kaohsiung City
- Linkou Chang Gung Memorial Hospital - New Taipei City
- Taipei Medical University - Shuang Ho Hospital - New Taipei City
- China Medical University Hospital - Taichung
- Taichung Veterans General Hospital - Taichung
- Taipei Veterans General Hospital - Taipei
Kentucky
- University of Kentucky Chandler Medical Center - Lexington
New Jersey
- JFK Neuroscience Institute, JFK Medical Center - Edison
Ohio
- The Ohio State University - Wexner Medical Center - Columbus
Tennessee
- Chattanooga Center for Neurologic Research - Chattanooga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-01-27 |
| Est. Completion | 2021-02-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04091945
The ClinicalTrials.gov registry entry for NCT04091945 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 351-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (93% lower). The listed sponsor is Lumosa Therapeutics Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Ischemic Stroke appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04091945 reports 10 study locations spanning 5 distinct geographic areas - top geographies include Other, Kentucky, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04091945 about?
NCT04091945 is a clinical study titled "A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS". This is a multicenter, double-blind, single-dose, randomized, and placebo-controlled prospective Phase IIa clinical study, designed to evaluate LT3001 drug product versus placebo/control in subjects with AIS.
What is the current status of trial NCT04091945?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2020-01-27. Estimated completion is 2021-02-22.
What conditions does trial NCT04091945 study?
This clinical trial studies the following conditions: Acute Ischemic Stroke.
What interventions are being tested in trial NCT04091945?
The interventions under investigation include: Placebo (DRUG), LT3001 Drug Product (DRUG).
Who is sponsoring clinical trial NCT04091945?
This trial is sponsored by Lumosa Therapeutics Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04091945 being conducted?
This trial has 10 study locations across Kentucky, New Jersey, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Transcranial Direct Current Stimulation for Treatment of Acute Ischemic Stroke
RECRUITING · Phase 2
-
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT
RECRUITING · Phase 2
-
Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)
RECRUITING · Phase 2
-
A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.